How to best measure HIV reservoirs?

Current Opinion in HIV and AIDS

Volumn 8, Issue 3, 2013, Pages 170-175

  Rouzioux, Christine ^a   Richman, Douglas ^b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

HIV latency; markers of HIV reservoirs; quantification

Indexed keywords

CD4 ANTIGEN; VIRUS DNA; VIRUS RNA;

BLOOD CELL; DISPERSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEASUREMENT ACCURACY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMARY INFECTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; T LYMPHOCYTE; VIREMIA; VIRUS CARRIER; VIRUS LATENCY; VIRUS REPLICATION;

BIOLOGICAL MARKERS; CARRIER STATE; DISEASE RESERVOIRS; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84876415088     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835fc619     Document Type: Review

References (57)

1. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
2. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
3. Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 2010; 82:1819-1828.
4. Lam YM, McBride KL, Amin J, et al. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PLoS One 2012; 7:e31990.
5. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
6. Richman DD. Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS 2011; 6:1-3.
7. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
8. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antire-troviral therapy. PLoS Pathog 2012; 8:e1002437.
9. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
10. + T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-1097.
11. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
12. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
13. Descours B, Avettand-Fenoel V, Blanc C, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54:1495-1503.
14. Ganesan A, Chattopadhyay PK, Brodie TM, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 2010; 201:272-284.
15. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PloS One 2009; 4:e6093.
16. Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 2012; 26:1473-1482.
17. Cobos-Jiménez V, Booiman T, Hamann J, Kootstra NA. Macrophages and HIV-1. Curr Opin HIV AIDS 2011; 6:385-390.
18. Eriksson S, Graf EH, Dahl V, et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PloS Pathog 2013; 9:e1003174.
19. Josefsson L, King MS, Makitalo B, et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci USA 2011; 108:11199-11204.
20. Schmid A, Gianella S, von Wyl V, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PloS One 2010; 5:e13310.
21. Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immuno-virological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010; 65:741-748.
22. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
23. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011; 25:885-897.
24. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
25. Vallejo A, Gutierrez C, Hernandez-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012; 26:1885-1894.
26. Avettand-Fenoel V, Boufassa F, Galimand J, et al. HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 2008; 42:399-404.
27. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
28. Blazkova J, Chun TW, Belay BW, et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012; 206:765-769.
29. Henrich TJ, Gallien S, Li JZ, et al. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods 2012; 186:68-72.
30. O'Doherty U, Swiggard WJ, Jeyakumar D, et al. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002; 76:10942-10950.
31. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 2009; 47:254-260.
32. Yu JJ, Wu TL, Liszewski MK, et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 2008; 379:78-86.
33. Sharkey M, Babic DZ, Greenough T, et al. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011; 7:e1001303.
34. Lewin SR, Murray JM, Solomon A, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:140-147.
35. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012; 26:543-550.
36. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
37. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
38. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcrip-tase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
39. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884.
40. Zheng L, Bosch RJ, Chan ES, et al. Predictors of residual viremia in patients on long-term suppressive antiretroviral therapy. Antivir Ther 2012; 20:.
41. Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to ser-opositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81:217-223.
42. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+T cell counts. JInfect Dis 2005; 192:46-55.
43. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-715.
44. Minga AK, Anglaret X, d' Aquin Toni T, et al. HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr 2008; 48:350-354.
45. Tsiara CG, Nikolopoulos GK, Bagos PG, et al. Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. AIDS Res Hum Retroviruses 2012; 28:366-373.
46. Julg B, Pereyra F, Buzon MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 2010; 51:233-238.
47. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
48. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
49. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-1056.
50. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunoviro-logic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
51. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antire-troviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001-1009.
52. Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252-1255.
53. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI study 2013. PLoS Pathog doi. 10.1371/journal.ppat.1003211.
54. Mexas AM, Graf EH, Pace MJ, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 2012; 26:2295-2306.
55. Agosto LM, Liszewski MK, Mexas A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology 2011; 409:46-53.
56. d'Ettorre G, Zaffiri L, Ceccarelli G, et al. The role of HIV-DNA testing in clinical practice. New Microbiol 2010; 33: 1-11.
57. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.